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Abstract
Background: AYX1 is an unmodified DNA-decoy designed to reduce acute post-surgical pain and its chronification with a
single intrathecal dose at the time of surgery. AYX1 inhibits the transcription factor early growth response protein 1, which is
transiently induced at the time of injury and triggers gene regulation in the dorsal root ganglia and spinal cord that leads to
long-term sensitization and pain. This work characterizes the AYX1 dose-response profile in rats and the link to AYX1
pharmacokinetics and metabolism in the cerebrospinal fluid, dorsal root ganglia, and spinal cord.
Results: The effects of ascending dose-levels of AYX1 on mechanical hypersensitivity were measured in the spared nerve
injury model of chronic pain and in a plantar incision model of acute post-surgical pain. AYX1 dose-response profile shows
that efficacy rapidly increases from a minimum effective dose of  0.5 mg to a peak maximum effective dose of  1 mg. With
further dose escalation, the efficacy paradoxically appears to decrease by  30% and then returns to full efficacy at the
maximum feasible dose of  4 mg. The reduction of efficacy is associated to doses triggering a near-saturation of AYX1
metabolism by nucleases in the cerebrospinal fluid and a paradoxical reduction of AYX1 exposure during the period of early
growth response protein 1 induction. This effect is overcome at higher doses that compensate for the effect of metabolism.
Discussion: AYX1 is a competitive antagonist of early growth response protein 1, which is consistent with the overall
increased efficacy observed as dose-levels initially escalate. Chemically, AYX1 is unprotected against degradation by nucleases. The sensitivity to nucleases is reflected in a paradoxical reduction of efficacy in the dose-response curve.
Conclusions: These findings point to the importance of the nuclease environment of the cerebrospinal fluid to the research
and development of AYX1 and other intrathecal nucleotide-based therapeutics.
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Introduction
Pain following surgery remains a major public health
issue with 80% of surgery patients suﬀering acute
pain and  10% to 50% developing chronic pain.1–4
The transition to chronic pain reﬂects the long-term sensitization of the dorsal root ganglia (DRG) and spinal
cord network triggered by surgical trauma.5 Upon such
trauma, the transcription factor early growth response
protein 1 (EGR1) is transiently induced in the DRG
and spinal cord and locally initiates genomic regulations
that establish long-lasting neuronal sensitization.6–10
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AYX1 is an unmodiﬁed double-stranded 23-bp
deoxyoligonucleotide, or DNA-decoy, with a sequence
that mimics the natural genomic DNA sequence bound
by EGR1 and speciﬁcally inhibits its activity.11 It is
delivered via a single intrathecal (IT) bolus injection
around the time of surgery to reduce acute pain and
prevent its chroniﬁcation. AYX1 eﬃcacy in animal
pain models has been described in a prior publication:
brieﬂy, a one-time administration provides up to 80%
reduction of mechanical hypersensitivity over controls.11
The preventive eﬀect can lasts for over a month (i.e., the
longest tested period in the rat spared nerve injury model
of chronic pain, at which point pain was resolving in
controls in our hands) and is observed across pain
models of complementary etiologies (e.g., tissue incision,
bone, or nerve injury).11 AYX1 is under active clinical
development (ADYX-004 trial, clinicaltrial.gov identiﬁer
NCT02081703).
We characterized the AYX1 dose-response proﬁle in
rats using the complementary spared nerve injury and
plantar incision models of pain. To be eﬀective, AYX1
must be present in the DRG-spinal cord network at sufﬁcient levels to inhibit EGR1. Prior studies in the spinal
cord have shown that EGR1 induction is detectable
from 30 to 60 min up to at least 12 h following a noxious or sensitizing stimulus.12,13 The pharmacokinetic
properties of single strand oligonucleotides are just
beginning to be understood14–17 and to the best of our
knowledge, no information is publicly available regarding IT injection of DNA-decoys as a class of molecules.
We characterized AYX1 local pharmacokinetics (PK)
and metabolism features driving AYX1 exposure in the
lumbar cerebrospinal ﬂuid (LCSF), DRG, and spinal
cord during that timeframe. These combined data
show that the AYX1 dose-response pattern is consistent
with the PK and metabolism features of AYX1 as an
oligonucleotide unprotected from nuclease-based
metabolism.

Methods
Animals
Sprague Dawley rats (Harlan industry or Charles River
Laboratories), 250 to 350 g were used. Experiments
were carried out according to animal care protocols
approved by the respective Institutional Animal Care
and Use Committees of each testing site and were
designed to minimize the amount of animals utilized.
The following number of rats were used: 35 rats for
the ADY-SNI2 pharmacology study (one rat in the vehicle group and one rat in the 1.05 mg AYX1 group were
excluded from the study due to autotomy and euthanasia
following surgery), 42 rats for the ADY-INC5 pharmacology study (no exclusion), 75 rats for the in vivo PK
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and metabolism work (no exclusion), 4 rats for the spinal
homogenate metabolism work (no exclusion), and 4 rats
for the histology presented here (no exclusion).

IT administration
AYX1 (sense strand: 50 -GTATGCGTGGGCGGTG
GGCGTAG-30 , antisense strand: 50 -CTACGCCCACC
GCCCACGCATAC-30 ) or vehicle were administered
intrathecally under anesthesia as a percutaneous bolus
at the L4/5 or L5/6 vertebral level at the time of surgery
as previously described in literature.11 IT injection
volume was 20 mL in the ADY-SNI2 and ADY-INC5
studies. For the PK experiments, 1.1 mg of AYX1 clinical formulation (110 mg/mL) was injected in 10 mL,
2.2 mg in 20 mL, and 3.85 mg in 35 mL to follow an
ascending dose-volume scheme similar to that of
AYX1 clinical trials (clinicaltrial.gov identiﬁer
NCT02081703).

Behavioral testing
The spared nerve injury and plantar incision models were
performed as described elsewhere.11 Rats were habituated to cages with mesh wire ﬂoors for at least 1 h
before testing. Calibrated von Frey hairs were applied
with the following pseudo-random pattern: 6, 1, 10, 4,
26, 10, and 8 g. For each testing level, the von Frey hair
was applied ﬁve times consecutively around the incision,
and the number of paw withdrawals (0–5 per level, 0–35
total) was recorded as a response. The time interval
between each testing level for a given rat was 3 min.
For each study, each tested cohort of animals included
controls. Testing was conducted by a single experimenter
at each testing site in a blinded fashion: blinded test and
control article vials were sent to the testing sites, and the
codes were only revealed after the entire testing was
completed.

Tissue sampling
For AYX1 concentration measurement, LCSF was collected percutaneously once at the L3/4 vertebral level in
separate groups of rats at 30, 60, 120, 240, 360, and
720 min following IT administration. The collection
was facilitated by pressing the neck and applying mechanical traction to the tail while holding the head of the
animal and/or inclining the animal’s position to an
approximate 45 angle as follow: rats were placed over
a stainless steel bowl to curve the lumbar portion of the
spinal cord/vertebra, anesthetized under 1% to 3% isoﬂurane using a nose mask, the animal head and forepaws
both taped to the nose mask to secure the animal and
allow the experimenter to gently apply traction to the tail
during collection. A 30G needle was inserted directly
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into the IT space to allow the LCSF to rise naturally by
diﬀerential pressure between the LCSF and the air outside the needle. The LCSF that rose in the needle hub
was then collected using a sterile insulin syringe and
needle. No impact of anesthesia was observed on
LCSF collection; 30 to 50 mL of LCSF were collected
per animal. Animals were then sacriﬁced, and DRG
and spinal cord from the T12 to T13 vertebral level (corresponding to the L1–L2 spinal level)18 to the sacral tip
were collected, washed in 1X phosphate buﬀered saline
(PBS), and frozen for subsequent AYX1 tissue uptake
analysis (DRG were pooled for each animal).

AYX1 analytical assay
AYX1 was quantiﬁed by Capillary Gel ElectrophoresisHybridization (CGEH). Samples were extracted using
phenol-chloroform and alcohol precipitation and hybridized to a ﬂuorescent-labeled probe speciﬁc to AYX1.
The probe-analyte species were separated and detected
using capillary electrophoresis with laser-induced ﬂuorescence and back-calculated to a matrix standard curve.
The assay allows detecting and quantifying N-1 to N-6
shortmer metabolites or shorter versions of AYX1 produced by nuclease-based nucleotide removal. Values
reported as ‘‘total AYX1’’ include full length plus shortmer metabolites.

Spinal cord homogenate incubation
Rats were anesthetized, exsanguinated with ice cold 1X
PBS, spinal cords harvested, washed in ice cold 1X PBS,
weighed, cut in pieces, pooled into 500 mL of ice-cold
nuclease buﬀer (100 mM tris-HCL and 1 mM magnesium
acetate, pH 8), and homogenized with a dounce homogenizer. AYX1-homogenate mixes were incubated at
37 C. Reactions were stopped with proteinase K
(100 mg/mL). For the EXOIII nuclease experiment, incubations were made using the reaction buﬀer provided
with the enzyme (Promega, WI, catalogue # M1811)
and stopped with 20 mM ethylene diamine tetraacetic
acid.

Histology
AYX1 was conjugated on the sense strand to an
ALEXA488 tag (50 ALEXA Fluor 488, NHS Ester,
IDTDNA, IL) and was injected IT as described
above. Thirty minutes following the injection, spinal
cord and DRG were collected in a dark room,
washed in saline, cryoprotected in sucrose, ﬁxed in
4% paraformaldehyde at 4 C, embedded, frozen on
dry ice, and mounted for cryostat sectioning. Tissue
sections of 12 mm were made and observed under ﬂuorescent microscope.

3

PK analysis
AYX1 and shortmers were analyzed by non-compartment methods (no modeling); AUC was estimated by
the trapezoid method; terminal slope and T1/2 were estimated by log-linear regression of 3þ points in the terminal phase; and T1/2 were not reported if the coeﬃcient
of regression R2 for the slope estimation was <0.8.

Statistical analysis
A non-parametric Student T-test, followed by a T-Welsh
analysis for uneven variance correction, was used to analyze individual conditions and whole data distribution
between experimental conditions (Excel 14.4.1). Dosedependent relationships were analyzed using analysis of
variance (GraphPad Prism 7.0a Software, La Jolla
California USA, www.graphpad.com). Data are presented throughout the article as Mean followed by
either a standard error (SE) or a standard error to the
mean.

Results
AYX1 dose-response profile
The AYX1 eﬃcacy proﬁle for reducing mechanical
hypersensitivity in rat models of acute and chronic
pain was ﬁrst described in Mamet et al.11 During
AYX1 preclinical development, seven independent studies were conducted to measure the eﬀect of ascending
doses of AYX1 on mechanical hypersensitivity following
a 20 mL IT injection at the time of an injury, including
the ﬁve studies described in Mamet et al. for which we
provide here a meta-analysis (Table 1).
The studies were performed at several US laboratories
and covered doses from 0.5 mg up to the maximum
feasible dose of  4 mg based on AYX1 solubility limit
and volume of IT injection. The AYX1 eﬃcacy proﬁle
was similar across studies: eﬃcacy appeared within 24 h
of injury and administration and lasted, at maximal eﬃcacy, until hypersensitivity was resolving in control animals regardless of whether pain was due to last a few
days or several weeks (see literature,11 Figure 1(a) and
(b) and Table 1). Across dose-levels, an increase of eﬃcacy was expressed as an increase in magnitude of pain
suppression compared to controls and as an increase in
the duration of that eﬀect, i.e., the eﬀect of sub-optimal
doses did not last until pain resolved in controls (see literature,11 Figure 1(a) and (b)).
To build up AYX1 dose-response in given study, the
eﬃcacy of each tested dose-level was measured as a percentage of reduction of area-under-the curve of total von
Frey responses compared to controls from the time of IT
injection and injury until the last day of testing. The
meta-analysis dose-responses across studies and pain
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Table 1. Dose-response across AYX1 pharmacology studies.

Pain model
Spared nerve
injury model

Plantar
incisional
model

Testing site

Study description

Study
duration

AYX1
dose (mg)

Efficacy
normed on
vehicle

SNI1

Stanford Uni.

Mamet et al., 2014

4 weeks

SNI2

Uni. of KY

Current publication

10 days

SNI3

Uni. of AZ

Mamet et al., 2014

10 days

SNI4

Uni. of KY

Mamet et al., 2014

4 weeks

INC2

Uni. of IA

Mamet et al., 2014

72 h

DOD1

Stanford Uni.

Mamet et al., 2014

72 h

INC5

Uni. of KY

Current publication

48 h

0.56
1.40
0.70
1.05
1.40
2.80
0.70
1.40
2.80
0.56
0.84
1.12
1.40
2.80
4.20
1.05
1.40
2.80
0.28
0.56
0.84
1.12
1.40
1.68
0.56
0.84
1.12
1.40
2.80
4.20

0.04
0.78
0.83
0.40
0.70
0.83
0.50
0.67
0.75
0.44
0.33
0.39
0.60
0.52
0.23
0.24
0.21
0.42
0.12
0.33
0.47
0.85
0.25
0.36
0.11
0.18
0.23
0.13
0.07
0.32

Study
name
(ADY-)

Efficacy
normed
on max.
efficacy
0.05
1.00
1.00
0.48
0.84
1.00
0.67
0.90
1.00
0.73
0.55
0.65
1.00
0.88
0.38
0.57
0.49
1.00
0.14
0.39
0.55
1.00
0.29
0.42
0.35
0.58
0.72
0.40
0.22
1.00

Analysis of
variance, p
<0.001
0.0001

0.001

0.004

0.03

<0.001

all groups :0.25
veh/2.8/4.2: 0.04
veh/1.12/4.2: 0.052
veh/1.12/2.8/4.2: 0.08

Note: veh: vehicle; Uni: University; AZ: Arizona; IA: Iowa; KY: Kentucky.
Individual dose-efficacy levels for each pharmacology study of the AYX1 dose-response meta-analysis. Efficacy normalized on vehicle and on maximum
efficacy within a given study: 0 ¼ no difference from vehicle, 1 ¼ 100% suppression of mechanical hypersensitivity compared to vehicle; ANOVA was used to
assess the strength of the dose-response in each study including the vehicle groups.

models were justiﬁed by the similarity of the AYX1 eﬃcacy proﬁle observed across those studies and pain
models. To allow for a sensitive analysis, data were
normalized for each study on the maximum eﬃcacy measured for that study. Both normalized and nonnormalized eﬃcacy values for each tested dose and
study are presented in Table 1. Examining individual
studies, the magnitude of AYX1 eﬃcacy rapidly
increases with dose until maximum eﬃcacy is reached,
suggesting an exponential association relationship
followed by a plateau of eﬃcacy (Figure 1(b) and

(c)). Interestingly, in four out of the seven studies
(ADY-SNI2, -SNI4, -INC5, -DOD1), one dose-level
produced a lower eﬃcacy than predicted, an outlier in
the overall dose-response pattern and exponential ﬁt
(Figure 1(b) and (c) and Table 1). The occurrence of
this observation across more than half of the studies in
complementary pain models and separate testing laboratories supports a real feature over the likelihood of a
random eﬀect. This feature is not only observed in individual studies but also conserved in the meta-analysis of
the combined seven studies which delineates the
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(a)

(b)

total
von Frey responses

total
von Frey responses
24

vehicle
20

18
16
14

vehicle

12

2.8 mg

16
1.05 mg

*

12

*

*

4

* *
0
0

*
*

*

1

*
*

*

*

*

*

1.4 mg

6

* 0.7 mg 4
2.8 mg 2

3

4
5
6
days post-surgery

7

8

9

10

0

24
hours post-surgery

(d)

AYX1 efficacy
(normed on max. efficacy)

48

AYX1 efficacy
(normed on max. efficacy)

1.0

1.0

0.8

0.8

0.6

0.6

0.4

0.4

0.2

0.2

0.0
0.8

4.2 mg

0
2

(c)

0.0

1.1 mg

**

8

*

8

*

10

*

1.6

2.4
3.2
AYX1 dose (mg)

4.0

4.8

0.0
0.0

0.8

1.6

2.4
3.2
AYX1 dose (mg)

4.0

4.8

Figure 1. (a) Effect of ascending AYX1 dose-levels on the development of pain measured as mechanical hypersensitivity in the spared
nerve injury model of chronic neuropathic pain in the ADY-SNI2 study. Total responses (number of paw withdrawals) to repetitive von Frey
stimulation in animals treated with vehicle (black circles), 0.7 mg (black squares), 1.05 mg (white squares), 1.4 mg (white circles), or 2.8 mg
(white lozenges) AYX1 are presented; T-test, different from vehicle at a given time-point: *p < 0.05, data distribution over the testing
period: p < 0.001 for all tested doses. Vehicle or AYX1 were administered once IT at the time of surgery, n ¼ 4 to 5 per group; values are
presented as mean þ SEM. (b) Effect of ascending AYX1 dose-levels on the development of pain measured as mechanical hypersensitivity in
the plantar incisional model of acute pain in the ADY-INC5 study. The effect of AYX1 0.56, 0.84, 1.12, 1.40, 2.80, and 4.20 mg was tested
against vehicle. For clarity in light of the amount of tested groups, the vehicle (black circles), 1.12 (black triangles), 2.8 (white circles), and
4.2 mg (white squares) of AYX1 groups are displayed as representative responses observed during the study. The magnitude of effects of all
tested doses is presented in Table 1. T-test followed by a T-Welsh analysis: *p ¼ 0.07, **p ¼ 0.02, data distribution over the testing period,
vehicle versus 4.2 mg: p ¼ 0.02; values are presented as mean þ SEM. Vehicle or AYX1 were administered once IT at the time of surgery,
n ¼ 6 per group. (c) and (d) Dose-response patterns observed in the ADY-SNI2 and ADY-INC5 studies, respectively. The magnitude of
effect for each dose-level normalized on the maximum efficacy measured within each study is presented (black triangles). Connecting
curves are presented as dotted lines. Data are fitted with an exponential association fit (dashed line), excluding the outlier dose (circled).
For the ADY-SNI2 study, excluding the outlier dose shifts the coefficient of regression R2 of the exponential fit from 0.75 to 0.97 and from
0.44 to 0.85 in the ADY-INC5 study.

following pattern: eﬃcacy rapidly increases from a minimum eﬃcacy dose of 0.5 mg, levels around 1 mg and as
the dose is further increased, eﬃcacy reduces by 30% in
average, and full eﬃcacy can be recovered for higher
doses up to the maximum feasible dose of 4 mg
(Figure 2). The general shape of the AYX1 dose-pattern
is consistent with its mechanism of action as a competitive
antagonist of EGR1 activity, with the exception of the

limited range of eﬃcacy reduction. To understand this
pattern of dose-response, we characterized AYX1 metabolism and PK in the lumbar DRG, spinal cord, and CSF.

AYX1 metabolism in spinal cord homogenates
AYX1 metabolism was characterized in fresh spinal cord
homogenates using concentrations from 0.001 fold to
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(a)

AYX1 efficacy
(normed on
max. efficacy)

1.2
1.0
0.8
0.6
0.4
0.2
0.0
0.4

0.8

1.2

1.6

2.0

2.4

2.8

3.2

3.6

4.0

4.4

-0.2
AYX1 (mg)
(b)

AYX1
shortmer metabolites
(ng/mL, lumbar CSF)

5.106

4.106

3.106

2.106

1.106

0.0
0.4

0.8

1.2

1.6

2.0

2.4

2.8

3.2

3.6

4.0

AYX1 (mg)
Figure 2. (a) Meta-analysis of AYX1 dose-response profile including results from the ADY-SNI2, INC5, SN1,2-4 (Mamet et al., 2014),
-INC25 (Mamet et al., 2014), and -DOD1 (Mamet et al., 2014) studies testing AYX1 efficacy in either the spared nerve injury of
neuropathic pain or in the incisional model of post-surgical pain. Data are normalized internally for each study against the maximum
observed efficacy relative to vehicle-treated animals and presented as mean  SEM. The connecting curve is presented with a dotted line,
and data fitted with a polynomial equation of the fourth order are presented as a dashed line. A systematic series of potential doseresponse fits were tested. The highest coefficients of regression were R2  0.35 for the polynomial fit above and equivalent or lower for
various association equations, including one-phase exponential or hyperbolic fits. In absence of a robust coefficient of regression and
considering that the polynomial curve fits the meta-analysis and the results of the majority of individual studies, it was selected as the
closest representation of AYX1 dose-response over a hyperbolic or exponential plateauing curve. (b) Concentration of AYX1 shortmers in
the LCSF 30 min following injection of 1.1, 2.2, or 3.85 mg of AYX1; n ¼ 5 per dose-level; results are presented as mean  SEM for each
dose-level. Data are fitted with a sigmoidal function (dotted line).
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Table 2. LCSF, DRG, and spinal pharmacokinetic parameters of AYX1 and shortmers metabolites.
Tissue

Variable

LCSF
AYX1

shortmers

Total
Lumbar DRG
AYX1

shortmers

Total
Lumbar spinal cord
AYX1

shortmers

Total

AYX1 (mg)/vol
(uL)

Cmax
(mg/mL)

T1/2
(min)

Tmax (min)

AUC (0-T)
(min*mg/mL)

AUC 60–720 min
(min*mg/mL)

1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35
1.1/10
2.2/20
3.85/35

3109
6469
9328
1430
3830
4688
4539
10300
13720
7.668
27.48
26.72
35.32
57.08
73.66
39.24
84.56
82.72
10.63
24.94
35.65
26.73
46.46
89.09
37.36
71.4
106.1

10.68
NR
9.592
205.1
NR
686.6
148.7
NR
NR
NR
NR
74.03
135.1
51.33
101.4
161.1
52.01
108.2
NR
104.6
54.74
189.2
47.86
NR
207.3
55.46
39.37

30
30
30
30
30
60
30
30
30
30
30
30
60
30
120
60
30
30
30
30
30
30
30
120
30
30
30

159,300
230,000
432,800
101,400
225,800
370,400
260,700
463,000
803,300
414
879
1305
2743
4364
10,750
3157
5365
12,060
651
836
1784
2384
3632
12,760
3035
4546
14,730

86,810
46,770
193,100
156,200
194,900
502,100
69,350
141,000
309,000
243
65.57
609.2
2847
3299
10,370
2604
3111
9761
441.4
110.7
868.2
2348
2936
12,190
1906
2747
11,140

Note: SE: standard error; NR: not reported; LCSF: lumbar cerebrospinal fluid; DRG: dorsal root ganglia.
Comparison of LCSF, DRG, and spinal cord pharmacokinetic parameters following a single IT administration of ascending dose-levels of AYX1. Individual
AYX1 and shortmer values are presented in Tables 3 and 4, respectively. When appropriate, the mg/mL units in the LCSF listed in the Cmax, AUC, Mean, SE,
and/or Median columns correspond to mg/mg of tissue units for the DRG and spinal cord tissues; N ¼ 4 to 5 rat per dose, time-point, and tissue.

5 to 10 fold the maximum spinal cord concentration
observed in vivo following a maximum feasible IT dose
(10–20 mg AYX1/mg of spinal cord, see Table 2). The
rate of AYX1 metabolism, measured after 5, 30, or
60 min of incubation, appeared as a linear function of
AYX1 concentration (Figure 3(a)). Saturation of metabolism, deﬁned as a plateau of metabolism rate despite an
increase in AYX1 concentration, was not attained even
at the highest tested concentration of 100 mg/mg of spinal
cord. Further, AYX1 rate of metabolism remained
slowed down over time (Figure 3(a)). This phenomenon
is common for oligonucleotides19–21 and has been
attributed to either a masking of oligonucleotides by
endogenous protein and/or by autoretardation due to
end-product inhibition.19,22,23 Incubation of AYX1
with a recombinant EXOIII nuclease showed a decrease

of metabolism similar to homogenates, suggesting AYX1
metabolism slows down via autoretardation versus nonspeciﬁc protein binding: 86,064, 19,258, and 8921 ng/
min, degradation rates were measured at 5, 30, and
60 min with the EXOIII compared to 92,309, 17,416,
and 9518 ng/min with the equivalent homogenate condition of 25 mg AYX1/mg.

AYX1 lumbar exposure and in vivo metabolism
EGR1 induction is detectable within 30 to 60 min
following a noxious stimulation.12,13 The histologic
visualization of a ﬂuorescent conjugate of AYX1 in
the lumbar spinal cord and DRG 30 min following an
IT injection shows that AYX1 is already present in cell
nuclei (Figure 4), where it can compete with the newly
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Figure 3. (a) Rate of AYX1 metabolism as a function of AYX1 concentration in fresh spinal cord homogenates. The rate of AYX1
metabolism is presented as the amount of full-length AYX1 degraded per minute as a function of AYX1 concentration introduced in the
homogenates. Data are presented for each measured time-point: 5 (circle), 30 (square), and 60 (triangle) min. Linear regression for each
data set are presented; coefficient of linear regression R2 is 0.99 for 5, 30, and 60 min; data are presented as mean þ SEM. (b) Metabolic
patterns of full-length AYX1 and individual N-1 to N-6 metabolites measured with the CGHE assay. For each analyzed sample, the relative
amount of AYX1 or individual metabolite species was normalized on the species found in largest amount. Each curve represents the
metabolite pattern observed for a dose-level, compartment, and time, and the corresponding concentration of total AYX1 is listed in the
legend. The amounts of N-4 to N-6 metabolites were pooled together due to the frequent fusion of their corresponding peaks in the
CGHE assay. Values are presented as mean þ SEM, n ¼ 2 to 4 per condition, FL ¼ full-length AYX1, N-x ¼ metabolite species. (c)
Illustration of electropherograms from the CGEH analytical method from the LCSF at 60 and 240 min following injection. Right arrows
show full-length AYX1 and the left arrows the extremity of the analyzable area. Peaks in between the two arrows represent AYX1
shortmers from N-1 to N-6.
LCSF: cerebrospinal fluid; DRG: dorsal root ganglia.

induced EGR1. EGR1 induction is known to continue
for at least 720 min following the initial stimulation, as
illustrated in the spinal cord.12,13 AYX1 exposure and
metabolism in the LCSF, DRG, and spinal cord was
studied during the overall period of EGR1 induction
using doses across the broad range of AYX1 eﬃcacious
dose-levels: 1.1, 2.2, and 3.85 mg. LCSF, DRG, and

spinal cord were collected at 30, 60, 120, 240, 360,
and 720 min post-injection. The presence of fulllength, intact AYX1 and N-1 to N-6 shortmer metabolites was measured using a CGEH method. The resulting PK parameters are shown in Table 2, and the
corresponding individual data-points are shown in
Tables 3 and 4.

Mamet et al.
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Figure 4. AYX1 presence in lumbar DRG (a) and spinal cord (b) cells was observed 30 min following an IT injection of 1.7 mg of AYX1
conjugated to an ALEX488 tag (green). Tissue auto-fluorescence was controlled using non-injected rats (c). Areas identified in the top
panels with white rectangles are magnified in the bottom panels. One example of AYX1-positive cell nuclei is pointed out for the DRG and
spinal cord with a vertical arrow. A few cells show AYX1 present in the cytoplasm, and one example is pointed out in both tissues by a
horizontal arrow. This observation is consistent with independent experiments showing the presence of decoys in the nucleus and/or
cytoplasm of cells following various administration methods47–49; Top panel scale bar ¼ 100 mm, bottom panel scale bar ¼ 25 mm, and n ¼ 2
rats per condition.

The maximal concentrations of AYX1 in the LCSF
increased with doses and were observed at 30 min, the
ﬁrst tested time-point and initial AYX1 concentrations
dropped by approximately 50-fold 120 min following
injection. This timeframe of rapid decrease corresponds
to a period of elevated AYX1 metabolism. This is
illustrated by the similar and maximal concentrations
of AYX1 shortmer metabolites measured at 30 min for
the mid and high AYX1 doses: 4393 and 3829 mg/
mL of shortmers in presence of 6468 and 9328 mg/mL
of intact AYX1, respectively (Table 4 and Figure 2(b)).
Maximal levels of shortmers further remained at
60 min for the high dose: 4688 mg/mL in presence
of 2678 mg/mL of intact AYX1, Table 4.
Subsequently, shortmer concentrations diminished and
leveled oﬀ while AYX1 concentrations continued to
drop in the low ng/mL range or below detection
limit. This is illustrated by the estimated T1/2, values
which were longer overall for the shortmers versus
AYX1 (Table 2).
The AYX1 exposure pattern in the DRG and spinal
cord was similar to that observed in the LCSF, with
concentrations largely dropping over the 120 min

following injection. However, initial AYX1 concentrations in the DRG and spinal cord after injection were
approximately three to four orders of magnitude lower
than the LCSF concentrations, and AYX1 was still present at 1 to 30 ng/mg of tissue after 720 min (Table 3).
The total exposure of AYX1 increased with doses
when calculated from the ﬁrst measured time-point of
30 min until the last time-point of 720 min. However,
the exposure at the mid dose was approximately half
that of the low dose exposure in the LCSF, DRG, and
spinal cord during the 60 min to 720 min timeframe
(Table 2). This observation correlates to the fact that
the mid dose of AYX1 engages a near-saturating rate
of metabolism in the LCSF during the ﬁrst 30 to
60 min period, as measured by shortmer concentrations,
while the low dose only produced a low metabolism rate
(Figure 2(b) and Tables 3 and 4).

Specificity of AYX1 metabolite patterns
The comparison of oligonucleotide shortmer metabolite
patterns, deﬁned as N-minus metabolite species and their
relative amounts, provides important clues as to the
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Table 3. LCSF, DRG, and spinal AYX1 concentrations for each AYX1 dose-level and at each measured time-point.
Tissue

AYX1 (mg)/vol (mL)

Time (min)

N

Mean (mg/mL)

SE (mg/mL)

Median (mg/mL)

LCSF

1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
2.2/20
2.2/20
2.2/20
2.2/20

30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240

5
4
4
4
4
4
5
4
4
3
4
4
5
4
4
4
4
4
5
4
4
4
4
4
5
4
4
4
5
3
5
4
4
4
5
3
5
4
4
4
4
4
5
4
4
4

3108.77196
1384.3966
41.587725
0.0126
0
0
6468.74928
720.017725
118.908725
0
0
0
9328.4782
2678.3156
360.532875
0.009575
0
0
7.667657941
3.920219497
0.007363318
0.004046355
0.001809653
0.034634755
27.47877045
0.753794535
0.217325199
0.000818852
0
0.003778745
26.71598671
7.017266029
2.069117621
0
0
0.01096018
10.63232418
7.284382244
0.006860178
0
0
0.020483504
24.93761384
1.517023367
0.180800152
0

255.6169484
259.9501099
19.92784122
0.0126
0
0
1180.29521
253.2146364
19.25506945
0
0
0
1351.11685
460.5476851
59.06257237
0.002292878
0
0
1.568782709
1.149641096
0.004430156
0.002597334
0.001809653
0.009110736
6.124114177
0.300554058
0.20848275
0.000818852
0
0.001988417
3.90767435
4.018598467
1.055901619
0
0
0.01096018
1.836208772
1.089622801
0.003963512
0
0
0.005724716
2.884383132
0.588309906
0.163416839
0

3023.6482
1464.5843
34.548
0
0
0
6613.3316
653.3905
114.92505
0
0
0
8870.9908
2908.1875
346.7795
0.00765
0
0
6.755526589
4.280427501
0.005836822
0.002656131
0
0.036514832
22.77076212
0.818188664
0.013328716
0
0
0.004594702
30.57879113
7.005950316
1.63809148
0
0
0
11.60045935
7.462844897
0.006678209
0
0
0.02144515
22.12447694
1.463704766
0.022397921
0

DRG

Spinal cord

(continued)
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Table 3. Continued
Tissue

AYX1 (mg)/vol (mL)

Time (min)

N

Mean (mg/mL)

SE (mg/mL)

Median (mg/mL)

2.2/20
2.2/20
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35

360
720
30
60
120
240
360
720

5
3
5
4
4
4
5
3

0.012175677
0.00295173
35.65144157
10.22149446
2.828536182
0
0
0.001916241

0.012175677
0.001746952
4.030442652
5.645387362
0.807271349
0
0
0.001916241

0
0.002808648
34.63588399
9.30448375
3.299263821
0
0
0

Note: LCSF: lumbar cerebrospinal fluid; DRG: dorsal root ganglia. Individual AYX1 concentration values over time following a single IT administration of
ascending dose-levels of AYX1. When appropriate, the mg/mL units in the LCSF section correspond to mg/mg of tissue units for the DRG and spinal cord
tissues sections.

Table 4. LCSF, DRG, and spinal shortmers concentrations for each AYX1 dose-level and at each measured time-point of AYX1.
Tissue

AYX1 (mg)/vol (mL)

Time (min)

N

Mean (mg/mL)

SE (mg/mL)

Median (mg/mL)

LCSF

1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
3.85/35

30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30

5
4
4
4
4
4
5
4
4
3
4
4
5
4
4
4
4
4
5
4
4
4
4
4
5
4
4
4
5
3
5

1430.47892
722.375275
115.585075
104.324925
51.365275
0
3829.55538
2007.303575
100.853425
60.56093333
71.01635
0
4393.03844
4687.99725
116.8175
97.2008
91.68185
0
22.31426526
35.32217034
2.732933554
0.897248086
0.486917073
0.076550053
57.08351415
30.66970954
12.41389241
0.939187865
0.68192968
0
56.00011489

457.7562697
138.4167534
5.6510067
5.841458069
22.46068157
0
420.6962055
675.1989776
6.898455803
2.884681372
11.75351275
0
228.2484032
518.3306593
10.05737843
14.20149944
5.90782032
0
7.072593559
3.163014365
1.658890882
0.058065924
0.249071141
0.026227013
4.243203582
14.66248569
11.36510465
0.338137454
0.169358434
0
16.31611509

997.2347
637.53445
119.2657
100.1125
54.9664
0
3382.6167
1944.99885
101.55215
62.9528
81.4557
0
4279.0878
4636.88145
113.8372
95.5283
92.64975
0
19.08379438
33.69677409
1.265015581
0.915116254
0.491545206
0.073519484
57.22032106
24.27906899
1.342176242
1.09900073
0.689466667
0
45.61231783

DRG

(continued)
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Table 4. Continued
Tissue

Spinal cord

AYX1 (mg)/vol (mL)

Time (min)

N

Mean (mg/mL)

SE (mg/mL)

Median (mg/mL)

3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
1.1/10
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
2.2/20
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35
3.85/35

60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720
30
60
120
240
360
720

4
4
4
5
3
5
4
4
4
4
4
5
4
4
4
5
3
5
4
4
4
5
3

46.00893874
73.66395684
1.186606863
0.912439333
0.052341893
26.72917591
21.61584808
4.363497293
0.896101046
0.354115198
0.134327203
46.45905314
33.94819926
6.627302761
0.729129583
0.435677476
0
70.43102964
32.68070379
89.08738192
9.125419048
1.035981222
0

26.07303081
21.06033945
0.086580168
0.038355346
0.052341893
1.243865375
9.123270579
3.022585718
0.084782621
0.182547597
0.077281886
13.54314857
9.294673064
5.294443044
0.306484997
0.224379814
0
19.07231587
19.29570307
14.96980246
8.069128587
0.117330072
0

42.59521031
62.82752407
1.144297059
0.933503571
0
25.68212152
17.85150049
1.393005601
0.872365
0.27566035
0.099909523
46.82376256
32.78052733
1.38740579
0.615999167
0.234685714
0
57.94835537
23.29563893
92.04840256
1.059888095
1.0491
0

Note: LCSF: lumbar cerebrospinal fluid; DRG: dorsal root ganglia. Individual AYX1 shortmer metabolites concentration values over time following a single IT
administration of ascending dose-levels of AYX1. When appropriate, the mg/mL units in the LCSF section correspond to mg/mg of tissue units for the DRG
and spinal cord tissues sections.

nuclease environments.20 The quantiﬁcation of N-1 to
N-6 AYX1 metabolites in the lumbar DRG, spinal
cord, and CSF at 60 and 240 min highlights speciﬁc patterns across overlapping concentrations of intact AYX1
plus shortmer metabolites, or total AYX1. DRG and
spinal cord patterns were similar at each measured
level of total AYX1 concentrations while LCSF patterns
varied from those with concentrations. DRG and LCSF
patterns are illustrated Figure 3(b) and (c). A high relative presence of AYX1 with decreasing amounts of individual metabolites of shorter length is observed in the
LCSF at 60 min with elevated concentrations of total
AYX1. At the same time-point in the DRG and spinal
cord, a low relative presence of AYX1 with increasing
amounts of shorter length metabolites is observed for
concentrations of total AYX1 that are approximately
two orders of magnitude lower. At 240 min, total
AYX1 concentrations are still two orders of magnitude
higher in the LCSF compared to local tissues, but the
same pattern of metabolites is now observed: a low relative presence of AYX1 with elevated N-2 and N-3
metabolites.

Discussion
AYX1 dose-response profile
AYX1 is a DNA-decoy administered once by the IT
route to prevent pain and its chroniﬁcation following
surgery or trauma. Its pharmacology for reducing mechanical hypersensitivity was characterized in multiple studies in the incisional (three studies) and spared nerve
injury (four studies) models of acute and chronic pain.
Across those studies, the average maximum eﬀect of
AYX1 measured as a reduction of area-under-the-curve
during the entire study period compared to controls was
65%  7.9% (SE), with a minimum eﬃcacy of 32%,
and a maximum eﬃcacy of 80% (Table 1). The associated dose-response pattern initially shows a rapid
increase of eﬃcacy from the minimally eﬃcacious dose
up to a maximum eﬃcacy with only a two-fold dose
increase. As doses further increase toward the maximum
feasible dose, a reduction of eﬃcacy followed by a recovery phase are observed in the majority of the individual
studies (Table 1) as well as in their meta-analyses. The
average peak dose found to reduce eﬃcacy across studies
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was 1.52 mg  0.44 mg (SE). Concurrently, the polynomial ﬁt of the dose-response meta-analysis places that
peak dose on the high end of that range at 2 mg.
Note that in one study (ADY-SNI4), a reduction of eﬃcacy was also observed at the maximum feasible dose,
based on AYX1 solubility limit and volume of IT injection. This result could be explained by AYX1 increased
viscosity at this concentration (i.e., 40 times higher than
water), which could lead to a variable distribution in the
LCSF across animals and studies. Of note, AYX1 doseresponse and its landmark features occur over a narrow
range of doses. This is similar to antisense oligonucleotides, with dose-response curves that often span within a
only 10-fold factor.24

AYX1 exposure in the LCSF, DRG, and spinal cord
To be eﬀective, AYX1 must inhibit EGR1 activity in
the DRG and/or spinal cord during EGR1 induction,11
from 30 to 60 min up to 12 h after a noxious stimulation.12,13 An increase of local AYX1 exposure during that timeframe is anticipated to increase eﬃcacy up
to an exposure level that exceeds what is required for a
complete inhibition of EGR1, which seems to occur for
doses 1 mg. The exposure of 2 mg AYX1 is two fold
lower in the LCSF and four times lower in the DRG and
spinal cord than that of 1 mg dose during that same
period. This likely results in a lower opposition to EGR1
action and could explain the paradoxical reduction of
eﬃcacy observed in the dose-response curve.
The paradoxical reduction in exposure appears to be
driven by the level of nuclease activity engaged in the
LCSF during the ﬁrst 30 to 60 min following injection:
the 2 mg dose was suﬃcient to trigger a rapid, nearsaturation of AYX1 metabolism while the 1 mg dose
only triggered a slow, basal metabolism. Consequently,
AYX1 concentration from the 2 mg dose (720 mg/
mL) was lower in the LCSF at 60 min compared to
the 1 mg dose (1400 mg/mL). At that time-point,
the concentrations of shortmers were 100 mg/mL for
both doses, suggesting that both doses were now associated with a similar and basal metabolism rate that
maintained their relative exposures onward. By direct
diﬀusion from the LCSF to the local tissues, the relative
positioning of exposure of the two doses appeared directly transferred to the DRG and spinal cord where
AYX1 exerts its pharmacological activity. For the
higher 4 mg dose, which also triggers a saturating
metabolism during the initial period following dosing,
the ‘‘excess’’ of AYX1 over the 2 mg dose appeared to
oﬀset an abrupt impact of the metabolism and its
exposure remained above that of the 1 mg dose after
60 min.
Those combined data suggest that the reduction in
eﬃcacy in the AYX1 dose-response pattern occurs for

13
the range of doses triggering near-saturation of metabolism in the LCSF upon injection: 1.5 to 2 mg AYX1.

Cerebrospinal fluid (CSF) nuclease environment
The CSF nuclease environment inﬂuences the AYX1
dose-response proﬁle. Our data suggest that it is a
multi-nuclease system with an elevated Km, hence with
a low aﬃnity of CSF nucleases for AYX1, and is rapidly
saturable. Indeed, the detection of several AYX1
metabolic patterns suggests that an increasing range of
nucleases metabolizes AYX1 as a function of concentration. Also, the presence of the same pattern of metabolites in the CSF and tissues at 240 min while total AYX1
concentrations are 2 order of magnitude higher suggests similar nucleases metabolize AYX1 but that in
the CSF, their aﬃnity for AYX1 is lower. This may
reﬂect the signiﬁcant inﬂuence of the composition of different environments (e.g., pH, metal ions, and salts) on
nuclease Km.25–27
Prior studies applying oligonucleotides to the CSF
reported an absence or a low nuclease activity in the
CSF while the analysis of the CSF proteome conﬁrms
the presence of several nucleases.28–30 The data from this
work provide a possible link between those apparently
contradictory observations: the CSF contains active
nucleases but their activity was not readily detected in
prior studies likely due the low oligonucleotide concentrations used (e.g., 0.1 mg/mL of CSF) compared to
AYX1 (i.e., 3–4 mg/mL).28,30 Lastly, the fact that the
metabolism remains saturated at 60 min for the high
dose in presence of concentrations of full-length AYX1
lower than metabolite concentrations suggests an hysteresis of the nucleases in the CSF, a phenomenon in
enzymology referring to enzymes which kinetics
responds slowly to rapid changes of substrate
concentrations.31

AYX1 tissue concentrations
During most of the EGR1 induction period, AYX1 concentrations in the DRG and spinal cord after injection of
eﬃcacious doses were in the low ng/mg of tissue range.
To understand the meaning of such concentrations, one
can estimate the number of AYX1 molecules per DRG
cell relative to the estimated number of EGR1 molecules
and EGR1 binding sites in the genome for an AYX1
concentration 10 ng/mg. Based on an average measured DRG weight of 1.79 mg (i.e., weight of a DRG
used in the PK work described above), 10 ng AYX1/mg
of DRG corresponds to 4.6 million AYX1 molecules
per cell (assuming 15,000 neurons32 and 10 satellite
cells per neuron per DRG and a negligible extracellular
space). The number of copies of a transcription factor
varies per cell from 5000 to 4,000,00033 and there are
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1000 to 1500 EGR1 binding sites per genome.34 Thus,
AYX1 concentrations in the ng/mg range represent biologically active concentrations as the corresponding, estimated amount of AYX1 molecules per cell within that
range can be in excess of the number of genomic EGR1
binding sites and potential EGR1 molecules.

AYX1, EGR1, and neurons
EGR1 can be expressed in a variety of cells including
neurons, glial, or immune cells to carry out complementary functions. In a nociceptive context, EGR1 induction
in the DRG and spinal cord appears speciﬁc to neurons
rather than glial cells as observed after peripheral nerve
injury, inﬂammation, thermal or mechanical noxious stimuli, and electrically induced-long term potentiation.12,13,35–37 This expression pattern directly
correlates to EGR1 core function of inducer of longterm neuronal sensitization.12,38 While macrophages
and other immune cells penetrate the spinal cord and
DRG to modulate pain signals in neuropathic pain situations, this happens signiﬁcantly after one or more days
post-injury,39–42 which is past the time of residence of
AYX1 in the LCSF and local neuronal tissues.
Altogether, EGR1 expression proﬁle and AYX1 PK support AYX1 focused action within EGR1-expressing neurons in the DRG and spinal cord rather than an action in
other cell types that can also express EGR1. The microscopic visualization of an AYX1-ﬂuorescent conjugate in
cells nuclei 30 min following an IT administration shows
that AYX1 penetrates cells rapidly. While the type of
cells taking up AYX1 cannot be determined from this
experiment, it is assumed that AYX1 enters neurons but
an entry in non-neural cells cannot be excluded. This
latter possibility is illustrated with the ﬁnding that antisense oligonucleotides can penetrate both neurons and
glia in the spinal cord.43 In terms of uptake mechanism,
AYX1 likely enters these cells via endocytic pathways,
which are common as well as saturable mechanisms of
entry for oligonucleotides.44,45

Conclusion
AYX1 is a DNA-decoy drug candidate that inhibits the
transcription factor EGR1 in the DRG-spinal cord network at the time of injury to reduce acute pain and its
chroniﬁcation. We show that AYX1 eﬃcacy increases
overall with dose. For doses that trigger a near-saturation of metabolism in the LCSF, however, local exposure
at AYX1 site of action can be reduced and associated to
a lowering of eﬃcacy. Additional mechanisms related to
the excess of metabolites associated with near-saturating
metabolism could also be at play. Since oligonucleotide
transport into cells is saturable and can be inhibited by
high oligonucleotide concentrations,45,46 it is possible
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that the excess of rapidly produced AYX1 metabolites
associated with the mid range doses competitively inhibit
cellular uptake while the level of full-length AYX1 is
already low, further supporting a reduction of eﬃcacy.
This hypothesis would require experimental conﬁrmation. Altogether, these data show that AYX1 pharmacology is directly tied to its mechanism of action
(inhibiting EGR1 over a period of time following
trauma), route of administration (local exposure in the
LCSF, DRG, and spinal cord), and its chemistry (an
unmodiﬁed oligonucleotide sensitive to nuclease
degradation).
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